Central Pacific Bank Trust Division Trims Position in Natera, Inc. (NASDAQ:NTRA)

Central Pacific Bank Trust Division trimmed its position in Natera, Inc. (NASDAQ:NTRA) by 28.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,648 shares of the medical research company’s stock after selling 1,462 shares during the period. Central Pacific Bank Trust Division’s holdings in Natera were worth $577,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of NTRA. Chartwell Investment Partners LLC lifted its stake in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Cerity Partners LLC raised its position in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after acquiring an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Natera during the 3rd quarter worth $385,000. Jag Capital Management LLC grew its position in shares of Natera by 8.8% during the 3rd quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock valued at $22,291,000 after acquiring an additional 14,159 shares during the period. Finally, First Turn Management LLC purchased a new stake in shares of Natera in the 3rd quarter worth $19,760,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. The Goldman Sachs Group lifted their price target on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Craig Hallum boosted their price target on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Piper Sandler boosted their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Finally, TD Cowen raised their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $153.67.

Insider Activity

In other Natera news, Director Rowan E. Chapman sold 1,767 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total value of $300,814.08. Following the transaction, the director now owns 6,202 shares of the company’s stock, valued at $1,055,828.48. This represents a 22.17 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider John Fesko sold 669 shares of Natera stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the sale, the insider now owns 114,142 shares of the company’s stock, valued at approximately $18,217,063.20. This trade represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,932 shares of company stock valued at $20,635,430. 7.60% of the stock is currently owned by insiders.

Natera Stock Up 4.4 %

NASDAQ NTRA opened at $167.60 on Friday. Natera, Inc. has a 52 week low of $58.53 and a 52 week high of $175.63. The firm has a market capitalization of $22.13 billion, a price-to-earnings ratio of -95.23 and a beta of 1.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average of $155.07 and a two-hundred day moving average of $129.83.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) EPS. On average, analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.